We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 23.50 | 1.38% | 1,728.50 | 1,727.50 | 1,728.50 | 1,729.50 | 1,695.50 | 1,705.00 | 6,275,082 | 16:35:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.44 | 71.14B |
From May 2022 to May 2024
By Anthony O. Goriainoff
GSK PLC said Friday that its respiratory syncytial virus, or RSV, vaccine candidate showed a statistically significant and clinically meaningful efficacy in adults aged 60 and over.
The London-listed pharmaceutical company said an efficacy analysis of the AReSVi 006 Phase 3 trial showed it offered exceptional protection for older adults from the serious consequences of RSV infection.
The company said it would start to engage with regulators immediately and that it expected regulatory submissions in the second half of the year.
"The AReSVi 006 trial will continue to evaluate both an annual revaccination schedule and longer-term protection over multiple seasons following one dose of the RSV older adult vaccine candidate," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
June 10, 2022 02:29 ET (06:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
